secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0001437749-24-034897
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Q3 net loss narrows to $14.1M; COVID Phase 2b sentinel enrollment near completion
--------------------------------------------------------------------------------

- Q3 revenue $4.9M (up from $2.1M YoY) from BARDA contracts; net loss per share $0.06 vs $0.11.
- Cash $58.7M; expects runway into 2026; R&D $15.1M, G&A $4.3M.
- Sentinel cohort enrollment of Phase 2b COVID vaccine trial expected to complete Nov 2024; 10,000-participant phase could start early 2025 if safety data favorable.
- FDA requested new clinical data for norovirus program; Vaxart created more potent GI.1 and GII.4 constructs.
- Preclinical data on HPV mucosal vaccine published in Vaccines in August 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924034897/0001437749-24-034897-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924034897/vxrt20240820_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-034897

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer